Tag #Drugapproval

Showing 1 to 3 of 3 results

euronews.com
🌐 85% Global Worthiness
News related image

EMA Rejects Alzheimer's Drug Donanemab Due to Safety Concerns

The European Medicines Agency (EMA) rejected Eli Lilly's Alzheimer's drug, donanemab, due to concerns about deadly side effects, impacting 7 million Europeans with Alzheimer's despite its 35% efficacy in slowing dementia progression in trials; the decision contrasts with the eventual approval of a s...

Progress

40% Bias Score

Good Health and Well-being
zeit.de
🌐 75% Global Worthiness
News related image

EMA Recommends Approval of Alzheimer's Drug Lecanemab

The European Medicines Agency (EMA) recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients with mild cognitive impairment or mild dementia after a previous rejection due to safety concerns; the drug only slightly slows disease progression and is suitable for a small patient su...

Progress

48% Bias Score

Good Health and Well-being
welt.de
🌐 85% Global Worthiness
News related image

EMA Recommends Approval of Alzheimer's Drug Lecanemab

The European Medicines Agency (EMA) again recommends approving Lecanemab, an Alzheimer's drug, for early-stage patients after previously rejecting it due to safety concerns; a new analysis shows benefits outweigh risks in a specific patient subgroup; the drug is already approved in the USA.

Progress

40% Bias Score

Good Health and Well-being

Showing 1 to 3 of 3 results